siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene

Journal of Controlled Release

Volumn 112, Issue 2, 2006, Pages 229-239

  Zhang, Chunling ^a   Tang, Ning ^a   Liu, XingJun ^a,b   Liang, Wei ^a   Xu, Wei ^a   Torchilin, Vladimir P ^c  

^a INSTITUTE OF BIOPHYSICS   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c NORTHEASTERN UNIVERSITY   (United States)

Author keywords

HDM2 gene; Liposomes; Lung cancer; Polyarginine; siRNA delivery

Indexed keywords

CELLS; GENE TRANSFER; POLYMERS; TOXICITY; TUMORS;

HDM2 GENE; LIPOSOMES; LUNG CANCER; POLYARGININE; SIRNA DELIVERY;

RNA;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N [METHOXY(POLYETHYLENE GLYCOL); LIPOFECTAMINE; LIPOSOME; MACROGOL DERIVATIVE; MESSENGER RNA; PLASMA PROTEIN; POLYARGININE; POLYOXYETHYLENE BIS(4 NITROPHENYLCARBONATE); PROTEIN MDM2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG STABILITY; DRUG TARGETING; ENCAPSULATION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INCUBATION TIME; LUNG CANCER; MOLECULE; NONVIRAL GENE DELIVERY SYSTEM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA DEGRADATION; RNA INTERFERENCE; RNA STABILITY; SERUM;

CELL LINE, TUMOR; CELL SURVIVAL; DRUG STABILITY; GENE SILENCING; GENE TARGETING; HUMANS; LIPOSOMES; OLIGOPEPTIDES; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, SMALL INTERFERING;

EID: 33646144003     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.01.022     Document Type: Article

References (31)

1. Novina C.D., and Sharp P.A. The RNAi revolution. Nature 430 (2004) 161-164
2. Elmen J., Thonberg H., Ljungberg K., Frieden M., Westergaard M., Xu Y., Wahren B., Liang Z., Orum H., Koch T., and Wahlestedt C. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 33 (2005) 439-447
3. Chiu Y.L., Ali A., Chu C.Y., Cao H., and Rana T.M. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem. Biol. 11 (2004) 1165-1175
4. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., Elbashir S., Geick A., Hadwiger P., Harborth J., John M., Kesavan V., Lavine G., Pandey R.K., Racie T., Rajeev K.G., Rohl I., Toudjarska I., Wang G., Wuschko S., Bumcrot D., Koteliansky V., Limmer S., Manoharan M., and Vornlocher H.P. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432 (2004) 173-1788
5. Schiffelers R.M., Ansari A., Xu J., Zhou Q., Tang Q., Storm G., Molema G., Lu P.Y., Scaria P.V., and Woodle M.C. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32 (2004) e149
6. Unnamalai N., Kang B.G., and Lee W.S. Cationic oligopeptide-mediated delivery of dsRNA for post-transcriptional gene silencing in plant cells. FEBS Lett. 566 (2004) 307-310
7. Lewin M., Carlesso N., Tung C.H., Tang X.W., Cory D., Scadden D.T., and Weissleder R. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 18 (2000) 410-414
8. Torchilin V.P., Rammohan R., Weissig V., and Levchenko T.S. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 8786-8791
9. Schwarze S.R., Ho A., and Vocero-Akbani S.F.A. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285 (1999) 1569-1572
10. Sharma A., and Sharma U.S. Liposomes in drug delivery: progress and limitations. Int. J. Pharm. 154 (1997) 123-140
11. Ma Z., Li J., He F., Wilson A., Pitt B., and Li S. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem. Biophys. Res. Commun. 330 (2005) 755-759
12. Spagnou S., Miller A.D., and Keller M. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 43 (2004) 13348-13356
13. Sioud M., and Sorensen D.R. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem. Biophys. Res. Commun. 312 (2003) 1220-1225
14. Dalby B., Cates S., Harris A., Ohki E.C., Tilkins M.L., Price P.J., and Ciccarone V.C. Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Methods 33 (2004) 95-103
15. Brazas R.M., and Hagstrom J.E. Delivery of small interfering RNA to mammalian cells in culture by using cationic lipid/polymer-based transfection reagents. Methods Enzymol. 392 (2005) 112-124
16. Ohki E.C., Tilkins M.L., Ciccarone V.C., and Price P.J. Improving the transfection efficiency of post-mitotic neurons. J. Neurosci. Methods 112 (2001) 95-99
17. Lorenz C., Hadwiger P., John M., Vornlocher H.P., and Unverzagt C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett. 14 (2004) 4975-4977
18. Vives E., Brodin P., and Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272 (1997) 16010-16017
19. Stroh M., Zimmer J.P., Duda D.G., Levchenko T.S., Cohen K.S., Cadden E.B.D.T.S., Torchilin V.P., Bawendi M.G., Fukumura D., and Jain R.K. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat. Med. 11 (2005) 678-682
20. Torchilin V.P., Levchenko T.S., Rammohan R., Volodina N., Papahadjopoulos-Sternberg B., and D'Souza G.G. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 1972-1977
21. Wender P.A., Mitchell D.J., Pattabiraman K., Pelkey E.T., Steinman L., and Rothbard J.B. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 13003-13008
22. Futaki S., Ohashi W., Suzuki T., Niwa M., Tanaka S., Ueda K., Harashima H., and Sugiura Y. Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjug. Chem. 12 (2001) 1005-10011
23. Liang W., Levchenko T., Khaw B.A., and Torchilin V.P. ATP-containing immunoliposomes specific for cardiac myosin. Curr. Drug Deliv. 1 (2004) 1-7
24. Enoch H.G., and Strittmatter P. Formation and properties of 1000-A-diameter, single-bilayer phospholipid vesicles. Proc. Natl. Acad. Sci. U. S. A. 76 (1979) 145-149
25. Lin Y., Yan X., Cao W., Wang C., Feng J., Duan J., and Xie S. Probing the structure of the SARS coronavirus using scanning electron microscopy. Antivir. Ther. 9 (2004) 287-289
26. Angelova M.I., Hristova N., and Tsoneva I. DNA-induced endocytosis upon local microinjection to giant unilamellar cationic vesicles. Eur. Biophys. J. 28 (1999) 142-150
27. Radler J.O., Koltover I., Salditt T., and Safinya C.R. Structure of DNA-cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes. Science 275 (1997) 810-814
28. Koltover I., Salditt T., Radler J.O., and Safinya C.R. An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. Science 281 (1998) 78-81
29. Lewis B.A., and Engelman D.M. Lipid bilayer thickness varies linearly with acyl chain length in fluid phosphatidylcholine vesicles. J. Mol. Biol. 166 (1983) 211-217
30. Wadia J.S., Stan R.V., and Dowdy S.F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10 (2004) 310-315
31. Fretz M.M., Koning G.A., Mastrobattista E., Jiskoot W., and Storm G. OVCAR-3 cells internalize TAT-peptide modified liposomes by endocytosis. Biochim. Biophys. Acta. 1665 (2004) 48-56